Joachim Rothe

Joachim (JR) Rothe, PhD, joined LSP in 2002 and is currently Managing Partner. Prior to joining LSP, Joachim was the Managing Director of MPM Capital Germany, a US healthcare investment firm, where he rose to head up their European investment franchise.

Previously, he worked at McKinsey & Company in Germany and at Roche in Switzerland. He serves or has served on the boards of 4-Antibody (CH, now NASDAQ: AGEN), Affectis (D), Binx Health (UK), Atugen (D, now LSE:SLN Silence Therapeutics), Bioxell (I, now SIX: Cosmo Pharma), Cardior (D), Cellerix (E, now Takeda), DNA Script (F), IDEA (D), Morphochem (D, now: Biovertis), Idenix (USA, then NASDAQ: IDIX, now Merck), Luxendo (D, now Bruker Corp), Nouscom (CH), Okairos (CH, now: GSK), Omrix Biopharmaceuticals (NYSE: OMRI, then J&J), Scion Pharmaceuticals (USA), SNIPR Biome (DK), t.Breeders (NASDAQ: Viacell, then NYSE:PKI) and U3 Pharma (D, now: Daiichi-Sankyo). He was closely involved in many other company creations, like Biomarin, Biovitrum, Omrix and Pharmasset.

In addition, he serves pro bono on the boards of various tech transfer organizations such as Ascenion, AWS, and is a director of the German Private Equity Association (BVK). Joachim obtained a Master’s degree in Biochemistry from the Free University in Berlin and a PhD in Molecular Immunology from Freiburg University. His thesis was supervised by Georges Köhler, a Nobel laureate in Medicine. Joachim has authored numerous articles in leading scientific publications, including Nature.